We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

National Survey on Infiltrative Breast Cancer (CSI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00696527
Recruitment Status : Completed
First Posted : June 12, 2008
Last Update Posted : December 10, 2010
Information provided by:

June 10, 2008
June 12, 2008
December 10, 2010
June 2007
July 2008   (Final data collection date for primary outcome measure)
Radiological, Clinical and Histological characteristics [ Time Frame: Once ]
Same as current
Complete list of historical versions of study NCT00696527 on ClinicalTrials.gov Archive Site
Treatments: Surgery, radiotherapy, chemotherapy, hormonotherapy. [ Time Frame: Once ]
Same as current
Not Provided
Not Provided
National Survey on Infiltrative Breast Cancer
National Prospective Survey on Women With a Diagnosis of Infiltrative Breast Cancer
The purpose of this observational study is to describe radiological, clinical and histological characteristics of women with infiltrative breast cancer.
Not Provided
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
First ten consecutive women with infiltrative breast cancer seen by oncologists, and fulfilling eligibility criteria.
Infiltrative Breast Cancer
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
July 2008
July 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women> or = 18 years old
  • Women with newly diagnosis of infiltrative breast cancer
  • Agree to take part in this study

Exclusion Criteria:

  • Women with other malignant tumor (except in situ cervical carcinoma or treated basal cell carcinoma)
  • Women with in situ ductal carcinoma or in situ lobular carcinoma
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
Not Provided
Study Director: Alain Castaigne, Medical Director AstraZeneca
December 2010